Advertisement

L'Endocrinologo

, Volume 16, Issue 6, pp 245–252 | Cite as

Terapia dell’ipoparatiroidismo con paratormone

  • Serena Palmieri
  • Cristina Eller-Vainicher
  • Iacopo Chiodini
Rassegna
  • 110 Downloads

Sommario

L’ipoparatiroidismo è l’unico deficit endocrino nel quale la terapia sostitutiva con l’ormone mancante, il paratormone (PTH), non è ancora in uso comune. La terapia convenzionale spesso non consente un soddisfacente controllo clinico e non previene la comparsa delle complicanze croniche. Il PTH 1-34 e PTH 1-84 hanno dimostrato di ridurre il fabbisogno di calcio e metaboliti attivi della vitamina D, di normalizzare le alterazioni del metabolismo osseo legate al deficit di PTH e di migliorare la qualità della vita dei pazienti.

Parole chiave

Ipoparatiroidismo Ipocalcemia Paratormone ricombinante PTH 1-34 PTH 1-84 

Notes

Conflitto di interesse

Gli autori Serena Palmieri, Cristina Eller-Vainicher e Iacopo Chiodini dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2015_161_MOESM1_ESM.doc (28 kb)
(DOC 29 kB)
40619_2015_161_MOESM2_ESM.doc (24 kb)
(DOC 25 kB)

Bibliografia

  1. 1.
    Bollerslev J, Rejnmark L, Marcocci C et al. (2015) European society of endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173(2):G1–G20 CrossRefPubMedGoogle Scholar
  2. 2.
    Cusano NE, Rubin MR, Irani D et al. (2013) Use of parathyroid hormone in hypoparathyroidism. J Endocrinol Invest 36(11):1121–1127 PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Winer KK, Ko CW, Reynolds JC et al. (2003) Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 88(9):4214–4220 CrossRefPubMedGoogle Scholar
  4. 4.
    Winer KK, Sinaii N, Reynolds J et al. (2010) Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab 95(6):2680–2688 PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Santonati A, Palermo A, Maddaloni E et al. (2015) PTH (1-34) for surgical hypoparathyroidism: a prospective open label investigation of efficacy and quality of life. J Clin Endocrinol Metab 100(9):3590–3597 CrossRefPubMedGoogle Scholar
  6. 6.
    Cusano NE, Rubin MR, McMahon DJ et al. (2013) Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab 98(1):137–144 PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Mannstadt M, Clarke BL, Vokes T et al. (2013) Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1(4):275–283 CrossRefPubMedGoogle Scholar
  8. 8.
    Rubin MR, Dempster DW, Sliney J Jr et al. (2011) PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res 26(11):2727–2736 PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Cusano NE, Rubin MR, McMahon DJ et al. (2013) The effect of PTH(1-84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98(6):2356–2361 PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Andrews EB, Gilsenan AW, Midkiff K et al. (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27(12):2429–2437 PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Cipriani C, Irani D, Bilezikian JP (2012) Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 27(12):2419–2428 CrossRefPubMedGoogle Scholar
  12. 12.
    Winer KK, Zhang B, Shrader JA et al. (2012) Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab 97(2):391–399 PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Winer KK, Fulton KA, Albert PS et al. (2014) Effects of Pump versus Twice-Daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J Pediatr 165(3):639 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2015

Authors and Affiliations

  • Serena Palmieri
    • 1
  • Cristina Eller-Vainicher
    • 1
  • Iacopo Chiodini
    • 1
  1. 1.Unità di Endocrinologia e Malattie MetabolicheFondazione IRCCS Ca’ Granda-Ospedale Maggiore PoliclinicoMilanoItalia

Personalised recommendations